Gene
CSF3R
CSF3R is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (2), Actionable biomarkers (1), Trial mentions (7), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention CSF3R. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 1 at the structurally incomplete recent edge.
CSF3R has 7 trial mentions across 5 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 1 of 8,875 | 0.01% | not measured | |
| 2024 | 2 of 8,597 | 0.02% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 7 of 11,460 | 0.06% |
| 2022 | 0 of 8,285 | 0.00% | 11 of 13,598 | 0.08% |
| 2021 | 2 of 8,692 | 0.02% | 12 of 15,045 | 0.08% |
| 2020 | 0 of 7,640 | 0.00% | 5 of 14,459 | 0.03% |
| 2019 | 0 of 7,300 | 0.00% | 5 of 12,159 | 0.04% |
| 2018 | 0 of 6,927 | 0.00% | 7 of 11,854 | 0.06% |
| 2017 | 0 of 6,558 | 0.00% | 3 of 11,595 | 0.03% |
Showing 10 of 37 years.
Assay-provider ledger (2)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Illumina | Unclassified | Clinical validationAnalytical validation | 1 | January 22, 2016 |
| NanoString Technologies | Unclassified | Clinical validationAnalytical validation | 1 | Date unknown |
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| CSF3R frameshift variant (D771),frameshift variant (S783) | Dasatinib | response-associated | No disease recorded | Cancer Genome Interpreter |
Trial mentions (7)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT07032727 | Trial eligibility (AACT) |
| NCT06056297 | Trial eligibility (AACT) |
| NCT06458244 | Trial eligibility (AACT) |
| NCT04526288 | Trial eligibility (AACT) |
| NCT02533362 | Trial eligibility (AACT) |
Showing 5 of 7 trial mentions.
Target-disease associations (481)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 3-dehydrocarnitine measurement | measurement | GWAS credible sets |
| 46,XX ovotesticular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX testicular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XY complete gonadal dysgenesis | cardiovascular disease | Mouse knockout (IMPC) |
| 46,XY disorder of sex development due to 5-alpha-reductase 2 deficiency | endocrine system disease | Mouse knockout (IMPC) |
Showing 5 of 481 associations.
Vendor sourcing (37)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v4.1.0 dataset. Predicted Consequence/Location: Missense variant. The majority of the known disease-causing variant... | View ClinVar record SCV007608490.1 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The CSF3R c.101C>T; p.Pro34Leu variant (rs34362628), to our knowledge, is not reported in the medical literature but is reported in ClinVar (Variation ID: 56... | View ClinVar record SCV005877226.1 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.160C>T (p.H54Y) alteration is located in exon 4 (coding exon 2) of the CSF3R gene. This alteration results from a C to T substitution at nucleotide pos... | View ClinVar record SCV003541430.2 |
| DASA (Brazil) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | NM_000760.4(CSF3R):c.1510G>A (p.Val504Met) is a missense variant that results in the substitution of valine with methionine. This variant is rare in populati... | View ClinVar record SCV007660828.2 |
| Fred Hutch Cancer Center | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * Acute myeloid leukemia (AML) other than acute promyelocytic leukemia (APL), myelodysplastic syndrome with excess blasts-2 (MDS-EB2), or another high-ris... | View trial NCT04526288 |
Showing 5 of 37 sourcing records.
Trial-cited literature (92)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Efbemalenograstim alfa not inferior to pegfilgrastim in providing neutrophil support in women with breast cancer undergoing myelotoxic chemotherapy: results of a phase 2 randomized, multicenter, open-label trial. | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer | 2024 | 6 |
| Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial. | Nature communications | 2023 | 28 |
| Adipocyte- and Monocyte-Mediated Vicious Circle of Inflammation and Obesity (Review of Cellular and Molecular Mechanisms). | International journal of molecular sciences | 2023 | 20 |
| A Comprehensive Narrative Review on the History, Current Landscape, and Future Directions of Hepatocellular Carcinoma (HCC) Systemic Therapy. | Cancers | 2023 | 16 |
| An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial. | Frontiers in immunology | 2023 | 14 |
Showing 5 of 92 papers.
Protein variant mentions (34)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A241V | 1 | 2015 | PMID 25741868 |
| p.A280V | 1 | 2019 | PMID 30675060 |
| p.D320N | 1 | 2015 | PMID 25741868 |
| p.D510H | 1 | 2015 | PMID 25741868 |
| p.D732N | 1 | 2015 | PMID 25741868 |
Showing 5 of 34 variants.
Literature-extracted relations (16)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Disease | associate |
The prognostic factors in acute myeloid leukaemia with double-mutated CCAAT/enhancer-binding protein alpha (CEBPAdm). | 2022 |
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Disease | associate |
Mutation topography and risk stratification for de novo acute myeloid leukaemia with normal cytogenetics and no nucleophosmin 1 (NPM1) mutation or Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD). | 2020 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Disease | associate |
Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. | 2020 |
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | Disease | associate |
Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. | 2020 |
| Leukemia, Neutrophilic, Chronic | Disease | associate |
Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. | 2020 |
Showing 5 of 16 relation assertions.
Organizations publishing (155)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 6 | 2009 to 2020 |
| Mount Sinai Health System | Hospital | 4 | 2015 to 2022 |
| Boston Children's Hospital | Hospital | 3 | 2015 to 2020 |
| Harvard Medical School | Academic | 3 | 2006 to 2021 |
| Kuwait University | Academic | 3 | 2015 to 2020 |
Showing 5 of 155 organizations.
Where CSF3R appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
417 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.